Claret, Laurent
Pentafragka, Christina
Karovic, Sanja
Zhao, Binsheng
Schwartz, Lawrence H.
Maitland, Michael L.
Bruno, Rene http://orcid.org/0000-0003-0200-039X
Funding for this research was provided by:
National Cancer Institute (NCI R01CA194783)
Article History
Received: 20 December 2017
Accepted: 20 April 2018
First Online: 26 April 2018
Compliance with ethical standards
:
: Laurent Claret and Rene Bruno were employees of Pharsight Consulting Services, Pharsight, a Certaraâ„¢ Company, when this work was performed. They are now employees of Genentech-Roche. Binsheng Zhao owns patents on tumor segmentation algorithms used in this work and has received royalties from Varian Medical Systems and Keosys Medical Imaging companies. Lawrence H. Schwartz received consulting fees from Merck, Novartis; and Research support from Daichi Sankyo and Eli Lilly. All other authors have no conflict of interest.
: This article does not contain any studies with animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.